Five things for pharma marketers to know: Friday, December 19

Five things for pharma marketers to know: Friday, December 19

Roche strikes out in cancer, Alzheimer's trials; Lilly in pact for fast-acting insulin; Humana revamps formulary.

Pfizer bets on Duchenne MD treatment

Pfizer bets on Duchenne MD treatment

The company moves on three leading contenders in the muscular dystrophy segment with the start of a Phase II trial

Apotex challenges Amgen blockbuster Neulasta

Canadian firm presents FDA with its third biosimilar application.

Merck buys Swiss biotech

The drugmaker announced it will acquire OncoEthix and its oncology candidate OTX015 in a deal worth up to $365 million

Five things for pharma marketers to know: Thursday, December 18

Five things for pharma marketers to know: Thursday, December 18

Shire may bid on NPS Pharmaceuticals; Amgen says cancer drug will cost $178,000; Takeda has a new head of R&D.

Pfizer urges parents to take the pledge against meningitis

Pfizer urges parents to take the pledge against meningitis

Pfizer has kicked off a disease-awareness campaign, "Take Action Against Meningitis," urging parents to discuss vaccinations with their healthcare providers with paralympic snowboarder Amy Purdy.

Court clears the way for Celebrex generics

Court clears the way for Celebrex generics

Ruling voids FDA's take on reissued patents, settling a year of challenges by generic applicants

Five things for pharma marketers to know: Wednesday, December 17

Five things for pharma marketers to know: Wednesday, December 17

UCB generic deal falls through; agency hiring could spike in 2015; teenage prescription drug abuse is on the decline.

Latest orphan-drug approval marks 15th this year

Latest orphan-drug approval marks 15th this year

Swiss drugmaker Novartis received an FDA nod for rare disease treatment Signifor LAR Tuesday, as orphan drug approvals reach new heights.

Brain cancer candidate touted for melanoma

Studies by Australian company Novogen are said to demonstrate, for the first time, that a drug highly effective against brain cancers has the same high potency against melanoma.

Pfizer brings humor to menopause marketing

Pfizer brings humor to menopause marketing

The new approach shows "The Talk" has a sequel.

Five things for pharma marketers to know: Tuesday, December 16

Five things for pharma marketers to know: Tuesday, December 16

Bayer consolidates OTC creative portfolio; Genentech R&D head steps down; Novartis receives approval for orphan drug.

Genentech drug combo targets advanced melanoma

The treatment reduces risk by half compared to widely used Zelboraf.

Bayer loses cancer drug patent fight in India

Court clears the way for a Nexavar generic from Natco

Sanofi, Regeneron field pre-launch cholesterol IQ poll

Sanofi, Regeneron field pre-launch cholesterol IQ poll

The drugmakers, who have an experimental cholesterol medication in the works, are asking consumers what they know about heart health.

FDA 2014 approvals outpace those of 2013

FDA 2014 approvals outpace those of 2013

The regulator noted in its early 2014 retrospective that it set a high mark for the number of approved rare disease drugs this year, and that insufficient information is the reason many breakthrough status requests get bounced.

Five things for pharma marketers to know: Monday, December 15

Five things for pharma marketers to know: Monday, December 15

United Healthcare tests an all-in-one cancer payment model, Pfizer inks a worldwide commercialization license for a human growth factor hormone, and the Commonwealth Fund grades Medicare as the program nears its 50th.

Five things for pharma marketers to know: Friday, December 12

Five things for pharma marketers to know: Friday, December 12

Judge rules Actavis must keep Alzheimer's drug on the market; Wyeth CEO joins Roche board, dispelling rumors he may be next Sanofi CEO; Two senators propose new FDA designation which would award 15 years of marketing exclusivity.

Antibiotics maker faces hurdles in diversifying beyond flagship drug

Antibiotics maker faces hurdles in diversifying beyond flagship drug

Cubist is re-launching its C.-Diff. antibiotic in an effort to jumpstart sales beyond Cubicin, which contributes most of its product revenue.

Pfizer's Lyrica ineffective at treating chronic back pain: study

Researchers found no difference between Lyrica (pregabalin) and placebo in treating lumbar spinal stenosis.

Sanofi looks to join M&A trend

Interim CEO Serge Weinberg tells a German paper that the company is prepared to buy assets that meet its goal of providing stable, steady growth.

Five things for pharma marketers to know, Thursday, December 11

Five things for pharma marketers to know, Thursday, December 11

Philadelphia Transportation Authority sues Gilead over Sovaldi sticker shock; Digital marketing tactics raise privacy concerns; another patent cliff is on the horizon.

Merck rolls out new Keytruda data in hard-to-treat group

Merck rolls out new Keytruda data in hard-to-treat group

The drugmaker shared early-trial results for its PD-1 among hard-to-tread triple-negative breast cancer patients and announced an effort to see if the drug can help patients overcome treatment resistance.

FDA plans review of Sandoz's Neupogen biosimilar

As courts sort out lawsuits over two Sandoz biosimilars, the Novartis unit reports a study showing its BLA candidate has similar efficacy to Neupogen.

Pfizer's Celebrex slammed by entry of generics

Mylan, Teva, and Actavis announced generics of the $3 billion arthritis drug.

Five things for pharma marketers to know: Wednesday, December 10

Five things for pharma marketers to know: Wednesday, December 10

Cubist's best-selling product has four of its five patents invalidated; the first biologic of AbbVie's Humira launches in India; Mylan debuts generic Celebrex.

Lilly psoriasis drug hits Phase-III endpoint

An investigational JAK inhibitor, baricitinib, bested placebo in moderate to severe plaque psoriasis in a Phase-III trial.

Patients to influence voice of Lemtrada consumer campaign

Patients to influence voice of Lemtrada consumer campaign

Patient advocates lobbied the FDA to approve the MS drug and Sanofi subsidiary Genzyme says their voice will be part of the consumer outreach when DTC rolls out next year.

Five things for pharma marketers to know: Tuesday, December 9

Five things for pharma marketers to know: Tuesday, December 9

WSJ reported FDA advisors failed to disclose pharma financial ties; Novartis axes 200 employees in New Jersey; Takeda retires the Millennium brand.

Indian merger creates fifth-largest generic drugmaker

Sun Pharma buys troubled Ranbaxy and its pipeline of promising follow-ons.

Positive lymphoma trials point to expanded role for immune therapies

Positive lymphoma trials point to expanded role for immune therapies

Merck's Keytruda and BMS's Opdivo reverse tumor growth in Hodgkin's patients studies.

AbbVie oncology pipeline continues to show progress

AbbVie oncology pipeline continues to show progress

Early trials of Venetoclax, formerly known as ABT-199, indicate the experimental drug execs consider an oncology cornerstone continues to show promise.

Five things for pharma marketers to know: Monday, December 8

Five things for pharma marketers to know: Monday, December 8

Merck buys up Cubist in an $8.4B deal, a jury sides with AstraZeneca in a generic Nexium lawsuit and the NYT finds a correlation between Genentech payments and Lucentis prescriptions.

A Call to Action for Healthcare Leaders: Why I Choose to Do More (And Why You Should, Too)

A Call to Action for Healthcare Leaders: Why I Choose to Do More (And Why You Should, Too)

"In this era, it requires mobilizing our collective intelligence toward innovation and integration that is meaningful for large populations."

Five things for pharma marketers to know: Friday, December 5

Five things for pharma marketers to know: Friday, December 5

GSK opts to hold onto $1.6 billion portfolio of older drugs; Sanofi upheavals continue with exit of US diabetes sales exec; Takeda gains breakthrough status on AL amyloidosis therapy.

Array gets binimetinib all to itself

Transfer of rights to the experimental cancer drug hinges on completion of Novartis/GSK asset swap.

Incyte drug gains expanded indication for bone marrow disease

Jakafi becomes the first drug approved for treating polycythemia vera.

GSK shrinks, and respiratory looks set to stumble

GSK shrinks, and respiratory looks set to stumble

Doctors tell investment firm Leerink they don't anticipate upping their prescriptions of the new Ellipta line.

Five for things pharma marketers to know: Thursday, December 4

Five for things pharma marketers to know: Thursday, December 4

Despite drugmaker discount, VA still can't afford Sovaldi without additional funds; Ousted Sanofi CEO Viehbacher faces lawsuit for an alleged kickback scheme; GSK slims sales and R&D workforce.

Trial recruiting looks to tap online community leaders

Trial recruiting looks to tap online community leaders

CureClick, TrialReach and WEGO team to leverage health communities and speed trial recruitment.

Rx-opioid related deaths fall for the first time in 13 years

Rx-opioid related deaths fall for the first time in 13 years

The bad news: heroin-related deaths inched upwards.

FDA approves Amgen leukemia immunotherapy

Amgen's Blincyto was approved for a rare form of leukemia after receiving Breakthrough Therapy designation and a Priority Review.

Lilly nabs rights for osteoporosis patch

The drugmaker inked a deal with Zosano worth up to $440 million for the product, which is about to enter Phase-III in clinical trials.

Five things for pharma marketers to know: Wednesday, December 3

Five things for pharma marketers to know: Wednesday, December 3

An Italian court backs the anti-trust's stand that Novartis and Roche colluded in Lucentis marketing; AstraZeneca is the test case for the court's new interpretation of pay-for-delay; early-stage results prompt Biogen Idec to take its experimental Alzheimer's treatment to Phase-III.

High deductibles, costs keep patients away

High deductibles, costs keep patients away

More cost data for the file the latest data shows that up-front healthcare costs are prompting many patients to delay office visits.

Actavis launches generic of Intuniv

The first low-cost version of the Shire ADHD drug benefits as a first-filer.

Five things for pharma marketers to know: Tuesday, December 2

Five things for pharma marketers to know: Tuesday, December 2

Otsuka acquires Avanir; hackers target pharma; Novartis must give up nicotine patch to finalize GSK consumer deal.

Insulin pump approval sets up showdown with Medtronic

Insulin pump approval sets up showdown with Medtronic

The approval adds a second option to a category that Medtronic has had to itself since 2006.

Baxter files long-acting hemophilia A treatment with FDA

US filing in hand, the company expects to submit drug for EMA approval in 2016.

Gilenya fails to help primary progressive MS patients

Novartis released Phase-III study results Monday.

World AIDS day highlights awareness gaps

World AIDS day highlights awareness gaps

The number of new HIV cases has held steady since the 1990s. Researchers note it is progress of a sort, but that driving numbers down requires one basic step: testing, testing, testing.

Five things for pharma marketers to know: Monday, December 1

Five things for pharma marketers to know: Monday, December 1

GSK is set to announce US job cuts this week, sales reps are getting the axe in China, and the FDA has rejected Avanir's inhalable migraine medication.

DDR on DTC: Tecfidera

DDR on DTC: Tecfidera

Tecfidera's visual pun fails to deliver Biogen's message

Insurer's maternity app rewards healthy behaviors

Insurer's maternity app rewards healthy behaviors

United Healthcare's Baby Blocks app seeks to become all-in-one hub for expectant moms and their babies.

Five things for pharma marketers to know: Wednesday, November 26

Five things for pharma marketers to know: Wednesday, November 26

Tecfidera gets label change; Amgen and AstraZeneca report psoriasis Phase-III antibody results; JAMA study reinforces statin guidelines.

Bayer launches respiratory awareness contest

Bayer launches respiratory awareness contest

Encouraging competitors to take an artistic approach to "Breathless Moments," the competition is a first for Bayer, which is already working on next year's effort.

Novartis employee terminated for falsifications

The scientist is also banned from receiving federal funding.

Bayer looks to exit diabetes device business

The German firm positions to focus on pharma pipeline and animal health.

Valeant adds to dermatology portfolio

Onexton is a first-and-only drug combination for treating acne.

Five things for pharma marketers to know: Tuesday, November 25

Five things for pharma marketers to know: Tuesday, November 25

AstraZeneca and Ranbaxy pay-for-delay case marches on; FDA extends Novartis multiple myeloma Priority Review timeline; Endo pays $25 for testosterone nasal gel.

FDA tempers opioid approval impact

FDA tempers opioid approval impact

The Center for Drug Evaluation and Research's director says there is a need for new opioids and cuts off dosing comparisons between extended-release and immediate-release opioids.

Vancouver tests prescription heroin

The north-of-the-border solution comes amid climbing heroin abuse in the US.

India to reorg pharmaceutical agencies

The reason: coordination and effectiveness.

Five things for pharma marketers to know: Monday, November 24

Five things for pharma marketers to know: Monday, November 24

BioMarin to acquire Dutch biotech Prosensa; Woodcock says significant efficacy key to Breakthrough Therapy designation; Stryker considers $16 billion bid for UK devicemaker Smith and Nephew.

Five things for pharma marketers to know: Friday, November 21

Five things for pharma marketers to know: Friday, November 21

EMA revises its conflict of interest policy; AbbVie all-oral HCV combo drug receives positive EU recommendation; Merck may help NewLink Genetics scale production of its Ebola vaccine.

Sanofi offers glimpse of next-gen. insulin strategy

Sanofi offers glimpse of next-gen. insulin strategy

In a company-hosted seminar today, the Paris-based drugmaker gave investors a preview of the future of its diabetes franchise.

World projected to spend $1T on drugs in 2018

World projected to spend $1T on drugs in 2018

The IMS Institute for Healthcare Informatics notes that developed markets remain a key driver.

Five things for pharma marketers to know: Thursday, November 20

Five things for pharma marketers to know: Thursday, November 20

CRS asks if high prices are a tool to offset CMS rebates, the FDA adds another DTC study to its lineup, and the NIH proposes making more clinical trial data public.

Unsealed court documents shed light on opioid marketing

Drug makers favor big spending on speakers' events and doctor outreach.

Gilead buys priority voucher for $125M

The scoop means the maker of HCV drugs Harvoni and Sovaldi can give any drug an accelerated review time.

Five things for pharma marketers to know: Wednesday, November 19

Five things for pharma marketers to know: Wednesday, November 19

Sanofi vets Takeda, devicemaker CEO candidates; Shaq returns for IcyHot; Royalty Pharma buys royalties on Vertex's Kalydeco.

Analyses support Pradaxa safety profile

Analyses support Pradaxa safety profile

Results of two post-market studies, conducted in part by Boehringer Ingelheim, corroborate the billion-dollar blood thinner's benefit/risk profile.

Tufts: drug dev costs have jumped 145%

Tufts: drug dev costs have jumped 145%

Researchers say the average cost of bringing a drug from concept to approval, and through post-approval assessments for reasons such as new doses or formulations, hovers at around $2.8 billion per drug in 2013 dollars.

PCSK9s stalk Merck's Vytorin

PCSK9s stalk Merck's Vytorin

A head-to-head comparison between Sanofi and Regeneron's experimental PCSK9 shows alirocumab lowers LDL levels more effectively than Merck's Zetia, which is part of the just-acquitted Vytorin.

Study finds new benefits in highly promising heart drug

A pipeline drug from Novartis has the potential to alter the progression of heart disease and keep patients out of the hospital.

Five things for pharma marketers to know: Tuesday, November 18

Five things for pharma marketers to know: Tuesday, November 18

Ackman walks away with $2.5 billion, despite no Allergan deal; Ranbaxy sues FDA over generic Nexium rights; Indian government's Health Ministry recommends breaking BMS cancer drug patent.

Merck's IMPROVE-IT trial hits big, supports wider Zetia use

Merck's IMPROVE-IT trial hits big, supports wider Zetia use

Patients taking Vytorin experienced a 6.4% reduced relative risk for cardiovascular events, the company said.

Inovio sticks with prostate cancer drug

The Pennsylvania company says it will continue to develop its IO treatment, even without Roche's support.

Five things for pharma marketers to know: Monday, November 17

Five things for pharma marketers to know: Monday, November 17

Actavis and Allergan have a $66-billion-dollar deal, Merck's Vytorin hits its endpoint, and Pfizer puts up $850 million for an experimental cancer drug.

Five things for pharma marketers to know: Friday, November 14

Five things for pharma marketers to know: Friday, November 14

Pfizer reportedly not interested in acquiring AZ; high deductible plans set to envelop healthcare insurance exchanges; GSK's mature drug portfolio finds a wholesale suitor.

HBA launches new look and programming

HBA launches new look and programming

The Healthcare Women's Business Association's new look comes with a side of new programming in an effort to reach more women in more places.

Valeant wins over docs with trips, fees

Valeant's war for Allergan also includes a soft touch when it comes to doctors: the WSJ reports that the company is winning over professionals with trips and consulting offers.

2015 an "important year" for Pfizer's IO pipeline, analysts say

A 4-1BB agonist highlights a discussion with analysts on the drug giant's immunoncology pipeline, with a number of combination options to be tested next year.

Five things for pharma marketers to know: Thursday, November 13

Five things for pharma marketers to know: Thursday, November 13

Actavis and Allergan are close to a deal in the $60-billionish range; AstraZeneca is working on a Brilinta antidote; scientists find what amounts to a naturally occurring version of Merck's Zetia.

Researchers: Pharmacy deserts contribute to access issues

Researchers: Pharmacy deserts contribute to access issues

Researchers studying the distribution of brick-and-mortar pharmacies in Chicago link adherence issues with geographic barriers to care.

Coalition urges gender-specific heart research

Coalition urges gender-specific heart research

The industry-supported group WomenHeart launched a heart failure awareness campaign Wednesday, as well as a push for gender-specific research.

Servier bets on match-stick-sized drug pump for diabetes drug

In a $1 billion deal, Servier will develop and market Intarcia Therapeutics' implantable device in markets outside the US and Japan.

Obesity drug war may be about more than marketing to the overweight

Obesity drug war may be about more than marketing to the overweight

Category news shows that marketing to the obese may mean marketing to related conditions.

Heart study results may be positive, but Vytorin boost unlikely

Heart study results may be positive, but Vytorin boost unlikely

An SEC filing by Merck suggests results of long awaited trial are favorable but come too late to have a commercial impact on sales of Vytorin and Zetia.

Merck HCV regimen only partially successful

Merck HCV regimen only partially successful

A Merck hep. C regimen that included two of its own agents paired with Gilead's Sovaldi faltered in four- and six-week regimens, according to analysts, leading to questions about the drugmaker's HCV prospects

Pradaxa antidote enters Phase III

Testing has already started abroad, and Boehringer says this is the first clinical trial that tests an antidote among patients taking a new oral anticoagulant.

Cigna lowers price of some HIV medications

The deal will cap the monthly price some patients may pay for medications such as Atripla.

Healthcare.gov reboot has new features

Patients will now be able to compare plans and identify ones that have disease-specific programs.

Five things for pharma marketers to know: Monday, November 10

Five things for pharma marketers to know: Monday, November 10

Dendreon goes Chapter 11; Mylan and Disney agree to EpiPen promotions; FDA pulls Ranbaxy generic claims for Nexium and Valcyte.

Five things for pharma marketers to know: Friday, November 7

Five things for pharma marketers to know: Friday, November 7

Woodcock says opioids without abuse-deterrent features are here to stay; UCB sells generic drug business to Advent and Avista; new antibiotic-free drug eradicates MRSA.

AstraZeneca Q3 sales rise, expects harsh 2015

AstraZeneca Q3 sales rise, expects harsh 2015

The company raised guidance for the end of the year and said Ranbaxy's being bounced from the Nexium competition probably means it has esomeprazole market to itself through 2014.

Ebola patient who used bio-filtration device reportedly free of virus

A medical device from Aethlon, used on an Ebola patient with multiple organ failure, was associated with promising results.

Five things for pharma marketers to know: Thursday, November 6

Five things for pharma marketers to know: Thursday, November 6

Eli Lilly's Cyramza approved for stomach and esophageal cancer; hedge fund may sue AbbVie for failed Shire acquisition; J&J's Olysio approved for use with Sovaldi.

CDC says cervical screening rates set to miss target

CDC says cervical screening rates set to miss target

The Centers for Disease Control and Prevention says 11.4% of women are still not screened for cervical cancer.

Microbiome linked to obesity

Researchers find that jet lag has an impact on the microscopic level.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters